Developing ICAM-1 for rhinovirus therapeutics

开发用于鼻病毒治疗的 ICAM-1

• 批准号: 7512407
• 负责人: Moonsoo M Jin
• 金额: $ 19.88万
• 依托单位: CORNELL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-15 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7512407
• 关键词: Acute; Affinity; Avidity; Bacteria; Binding; Cell Adhesion Molecules; Cell Death; Clinical Trials; Common Cold; Data; Development; Disease; Disruption; Dissociation; Engineering; Extracellular Domain; Fluorescence; Genes; Hela Cells; Human; Immunoglobulins; Individual; Infection; Intercellular Adhesion Molecules; Intercellular adhesion molecule 1; Lead; Life; Mammalian Cell; Monitor; N-terminal; Numbers; Post-Translational Protein Processing; Production; Proteins; Public Health; RNA; Recombinants; Rhinovirus; Sedimentation process; Serotyping; Surface Plasmon Resonance; System; Techniques; Testing; Therapeutic; Time; Transmission Electron Microscopy; Vaccination; Viral; Virus; Virus Activation; Virus Diseases; Yeasts; cost; directed evolution; extracellular; inhibitor/antagonist; mutant; prophylactic; receptor; recombinant virus

DESCRIPTION (provided by applicant): Human rhinoviruses (HRV) are the major causative agent of the common cold and the most common acute infectious illness in humans. Due to the large number of HRV serotypes, little immunological protection is offered by prior rhinovirus exposure, rendering vaccination approaches ineffective. In most people, HRV does not cause severe disease; however, in the case of asthmatics and immuno-compromised individuals, HRV infection can lead to life threatening complications. Of the 102 HRV serotypes, 90% use intercellular adhesion molecule (ICAM)-1 as a host receptor. Soluble ICAM-1 containing only the extracellular domains has shown some prophylactic and therapeutic benefit in clinical trials. Its effect against rhinovirus was likely due to the neutralization and disruption of the virus by ICAM-1 as a decoy. Further development of ICAM-1 for use in rhinovirus therapeutics has been hampered by the high cost of production of soluble ICAM-1 in mammalian cells. ICAM-1 contains five extracellular immunoglobulin (Ig) superfamily domains, and structural studies have indicated that only the first N-terminal domain (D1) is directly involved in binding to rhinovirus. We hypothesize that ICAM-1 D1 is sufficient to neutralize and disrupt rhinovirus. Moreover, the use of D1 alone may permit large-scale and low-cost production in a bacterial system as it lacks any eukaryotic posttranslational modification. Attempts to produce D1 alone thus far have not been successful, as D1 does not fold without D2. However, preliminary data herein suggest that functional D1 mutants capable of neutralizing rhinovirus can be engineered for large-scale production in bacteria. We also hypothesize that directed evolution of D1 toward higher affinity to the rhinovirus and greater potency for induction of virus dissociation will poise D1 to be effective for rhinovirus therapeutics. Our specific aims are: 1. To validate the efficacy of engineered ICAM-1 D1 in rhinovirus therapeutics. a. ICAM-1 D1 mutants will be examined for their ability to bind to rhinovirus by SPR and to induce virus disruption using a sedimentation technique and TEM. b. The potency of the D1 mutants in inhibiting virus infection will be quantified by a reduction in PFU. c. We will construct recombinant rhinoviruses (HRV14 and HRV16) that carry a gene encoding enhanced green fluorescence protein (eGFP) for real-time monitoring of virus propagation and to provide a sensitive means to test the potency of ICAM-1. 2. To engineer ICAM-1 D1 to be a more potent rhinovirus inhibitor by evolving D1 for higher affinity and avidity. a. Functional ICAM-1 D1 will be further subjected to directed evolution, using a yeast display system, for high affinity binding to HRV3, HRV14, and HRV16. b. Functional D1 mutant will be produced into dimeric, trimeric, and tetrameric forms to increase its affinity to the virus by avidity effect. c. We will examine the effect of the affinity of the D1 mutants to the viruses on their potency to induce viral disruption and to inhibit virus-induced cytopathic effects. PUBLIC HEALTH RELEVANCE Human rhinoviruses (HRV) are the major causative agent of the common cold and the most common acute infectious illness in humans. In most people, HRV does not cause severe disease; however, in the case of asthmatics and immuno-compromised individuals, HRV infection can lead to life threatening complications. In this study we propose to develop rhinovirus therapeutics utilizing host receptor as a decoy that will be effective against 90% of the rhinovirus serotypes.

描述(申请人提供)：人类鼻病毒(HRV)是普通感冒的主要病原体，也是人类最常见的急性传染病。由于HRV血清型很多，以前接触鼻病毒提供的免疫保护很少，导致疫苗接种方法无效。在大多数人中，HRV不会导致严重的疾病；然而，在哮喘患者和免疫功能低下的人中，HRV感染可能会导致危及生命的并发症。在102个HRV血清型中，90%使用细胞间黏附分子-1作为宿主受体。仅含有胞外结构域的可溶性ICAM-1已在临床试验中显示出一些预防和治疗的益处。其抗鼻病毒作用可能是由于ICAM-1作为诱饵对病毒的中和和破坏作用。用于鼻病毒治疗的ICAM-1的进一步开发一直受到在哺乳动物细胞中生产可溶性ICAM-1的高昂成本的阻碍。ICAM-1包含5个细胞外免疫球蛋白(Ig)超家族结构域，结构研究表明只有第一个N末端结构域(D1)直接参与与鼻病毒的结合。我们假设ICAM-1d1足以中和和破坏鼻病毒。此外，单独使用D1可能允许在细菌系统中大规模和低成本地生产，因为它缺乏任何真核翻译后修饰。单独生产d1的尝试到目前为止还没有成功，因为d1没有d2就不能折叠。然而，这里的初步数据表明，能够中和鼻病毒的功能性D1突变体可以被改造成大规模在细菌中生产。我们还假设，将D1定向进化为更高的对鼻病毒的亲和力和更大的诱导病毒解离的效力将使D1对鼻病毒的治疗有效。我们的具体目标是：1.验证重组ICAM-1D1在鼻病毒治疗中的疗效。A.ICAM-1D1突变体将通过SPR与鼻病毒结合，并使用沉淀法和透射电子显微镜检测其诱导病毒破坏的能力。B.d1突变体抑制病毒感染的效力将通过pfu的减少来量化。C.我们将构建携带增强型绿色荧光蛋白(EGFP)基因的重组鼻病毒(HRV14和HRV16)，用于实时监测病毒的传播，并为检测ICAM-1的效力提供灵敏的手段。2.通过进化出更高亲和力和亲和力的d1，使ICAM-1d1成为更有效的鼻病毒抑制因子。A.将使用酵母展示系统进一步对功能性ICAM-1 D1进行定向进化，以与HRV3、HRV14和HRV16进行高亲和力结合。B.功能性的d1突变体将产生二聚体、三聚体和四聚体形式，以通过亲和力效应增加其对病毒的亲和力。C.我们将研究D1突变体对病毒的亲和力对其诱导病毒破坏和抑制病毒诱导的细胞病变效应的效力的影响。人类鼻病毒(HRV)是普通感冒的主要病原体，也是人类最常见的急性传染病。在大多数人中，HRV不会导致严重的疾病；然而，在哮喘患者和免疫功能低下的人中，HRV感染可能会导致危及生命的并发症。在这项研究中，我们建议开发利用宿主受体作为诱饵的鼻病毒治疗药物，该药物将对90%的鼻病毒血清型有效。